{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:44:04Z","timestamp":1756993444613,"version":"3.28.0"},"reference-count":22,"publisher":"Texas Heart Institute Journal","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n Current venous thromboembolism guidelines recommend using direct oral anticoagulants (DOACs) over warfarin regardless of obesity status; however, evidence remains limited for the safety and efficacy of DOAC use in patients with obesity. This retrospective analysis sought to demonstrate the safety and efficacy of DOACs compared with warfarin in a diverse population of patients with obesity in light of current prescribing practices.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n A retrospective cohort study was conducted at a large academic health system between July 2014 and September 2019. Adults with an admission diagnosis of deep vein thrombosis (DVT) or pulmonary embolism, with weight greater than 120 kg or a body mass index greater than 40, and who were discharged on an oral anticoagulant were included. Outcomes included occurrence of a thromboembolic event (DVT, pulmonary embolism, or ischemic stroke), bleeding event requiring hospitalization, and all-cause mortality within 12 months following index admission.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Out of 787 patients included, 520 were in the DOAC group and 267 were in the warfarin group. Within 12 months of index hospitalization, thromboembolic events occurred in 4.23% of patients in the DOAC group vs 7.12% of patients in the warfarin group (hazard ratio, 0.6 [95% CI, 0.32-1.1]; P<\/jats:italic> = .082). Bleeding events requiring hospitalization occurred in 8.85% of DOAC patients vs 10.1% of warfarin patients (hazard ratio, 0.93 [95% CI, 0.57-1.5]; P<\/jats:italic> = .82). A DVT occurred in 1.7% and 4.9% of patients in the DOAC and warfarin groups, respectively (hazard ratio, 0.35 [95% CI, 0.15-0.84]; P<\/jats:italic> = .046).<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n No significant differences could be determined between DOACs and warfarin for cumulative thromboembolic or bleeding events, pulmonary embolism, ischemic stroke, or all-cause mortality. The risk of DVT was lower with apixaban and rivaroxaban. Regardless of patient weight or body mass index, physicians prescribed DOACs more commonly than warfarin.<\/jats:p>\n <\/jats:sec>","DOI":"10.14503\/thij-23-8260","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T15:26:35Z","timestamp":1715786795000},"source":"Crossref","is-referenced-by-count":2,"title":["Safety and Efficacy of Direct Oral Anticoagulants vs Warfarin in Patients With Obesity and Venous Thromboembolism: A Retrospective Analysis"],"prefix":"10.14503","volume":"51","author":[{"given":"Zoe H.","family":"Tu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Houston Methodist Hospital, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro D.","family":"Perez","sequence":"additional","affiliation":[{"name":"University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Diaz","sequence":"additional","affiliation":[{"name":"University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew S.","family":"Loop","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes Research and Policy, Auburn University Harrison College of Pharmacy, Auburn, Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Clarke","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Novant Health New Hanover Regional Medical Center, Wilmington, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5628","reference":[{"issue":"4","key":"b1","series-title":"Open J Prev Med","first-page":"499","article-title":"The effects of obesity on venous thromboembolism: a review","volume":"2","author":"Yang\n G","year":"2012","unstructured":"Yang\n G\n , de StaerckeC, HooperWC. The effects of obesity on venous thromboembolism: a review. Open J Prev Med. 2012;2(4):499-509. doi:10.4236\/ojpm.2012.24069"},{"issue":"3","key":"b2","series-title":"Eur J Haematol","first-page":"306","article-title":"The hematologic consequences of obesity","volume":"106","author":"Purdy\n JC","year":"2021","unstructured":"Purdy\n JC\n , ShatzelJJ. The hematologic consequences of obesity. Eur J Haematol. 2021;106(3):306-319. doi:10.1111\/ejh.13560"},{"issue":"3","key":"b3","series-title":"J Vasc Surg","first-page":"664","article-title":"Impact of obesity on venous hemodynamics of the lower limbs","volume":"52","author":"Willenberg\n T","year":"2010","unstructured":"Willenberg\n T\n , SchumacherA, Amann-VestiB, et al.\n Impact of obesity on venous hemodynamics of the lower limbs. J Vasc Surg. 2010;52(3):664-668. doi:10.1016\/j.jvs.2010.04.023"},{"issue":"4","key":"b4","series-title":"Thromb Haemost","first-page":"683","article-title":"Association between obesity and a prothrombotic state: the Framingham Offspring Study","volume":"91","author":"Rosito\n GA","year":"2004","unstructured":"Rosito\n GA\n , D\u2019AgostinoRB, MassaroJ, et al.\n Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost. 2004;91(4):683-689. doi:10.1160\/th03-01-0014"},{"key":"b5","series-title":"Thromb Res","first-page":"27","article-title":"Epidemiology of venous thromboembolism in the Framingham Heart Study","volume":"145","author":"Puurunen\n MK","year":"2016","unstructured":"Puurunen\n MK\n , GonaPN, LarsonMG, MurabitoJM, MagnaniJW, O\u2019DonnellCJ. Epidemiology of venous thromboembolism in the Framingham Heart Study. Thromb Res. 2016;145:27-33. doi:10.1016\/j.thromres.2016.06.033"},{"issue":"2","key":"b6","series-title":"Med Pharm Rep","first-page":"162","article-title":"Association between obesity and venous thromboembolism","volume":"93","author":"Hotoleanu\n C","year":"2020","unstructured":"Hotoleanu\n C\n \n . Association between obesity and venous thromboembolism. Med Pharm Rep. 2020;93(2):162-168. doi:10.15386\/mpr-1372"},{"issue":"5","key":"b7","series-title":"J Intern Med","first-page":"573","article-title":"Obesity as a causal risk factor for deep venous thrombosis: a Mendelian randomization study","volume":"277","author":"Klovaite\n J","year":"2015","unstructured":"Klovaite\n J\n , BennM, NordestgaardBG. Obesity as a causal risk factor for deep venous thrombosis: a Mendelian randomization study. J Intern Med. 2015;277(5):573-584. doi:10.1111\/joim.12299"},{"issue":"15","key":"b8","series-title":"Arch Intern Med","first-page":"1678","article-title":"Overweight, obesity, and the risk of recurrent venous thromboembolism","volume":"168","author":"Eichinger\n S","year":"2008","unstructured":"Eichinger\n S\n , HronG, BialonczykC, et al.\n Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med. 2008;168(15):1678-1683. doi:10.1001\/archinte.168.15.1678"},{"issue":"6","key":"b9","series-title":"Chest","first-page":"e545","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens\n SM","year":"2021","unstructured":"Stevens\n SM\n , WollerSC, KreuzigerLB, et al.\n Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545-e608. doi:10.1016\/j.chest.2021.07.055"},{"issue":"8","key":"b10","series-title":"J Thromb Haemost","first-page":"1874","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Martin\n KA","year":"2021","unstructured":"Martin\n KA\n , Beyer-WestendorfJ, DavidsonBL, HuismanMV, SandsetPM, MollS. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021;19(8):1874-1882. doi:10.1111\/jth.15358"},{"issue":"7","key":"b11","series-title":"Lancet Haematol","first-page":"e359","article-title":"Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data","volume":"6","author":"Kushnir\n M","year":"2019","unstructured":"Kushnir\n M\n , ChoiY, EisenbergR, et al.\n Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Lancet Haematol. 2019;6(7):e359-e365. doi:10.1016\/S2352-3026(19)30086-9"},{"key":"b12","series-title":"Thromb Res","first-page":"159","article-title":"Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: comparative effectiveness, safety, and costs","volume":"182","author":"Spyropoulos\n AC","year":"2019","unstructured":"Spyropoulos\n AC\n , AshtonV, ChenYW, WuB, PetersonED. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: comparative effectiveness, safety, and costs. Thromb Res. 2019;182:159-166. doi:10.1016\/j.thromres.2019.08.021"},{"issue":"2","key":"b13","series-title":"Pharmacotherapy","first-page":"119","article-title":"Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity","volume":"42","author":"Crouch\n A","year":"2022","unstructured":"Crouch\n A\n , NgTH, KelleyD, KnightT, EdwinS, GiulianoC; ASCEND-HIGHER. Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity. Pharmacotherapy. 2022;42(2):119-133. doi:10.1002\/phar.2655"},{"issue":"2","key":"b14","series-title":"J Thromb Thrombolysis","first-page":"349","article-title":"Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data","volume":"51","author":"Costa\n OS","year":"2021","unstructured":"Costa\n OS\n , Beyer-WestendorfJ, AshtonV, et al.\n Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data. J Thromb Thrombolysis. 2021;51(2):349-358. doi:10.1007\/s11239-020-02199-0"},{"issue":"2","key":"b15","series-title":"J Clin Med","first-page":"200","article-title":"Effectiveness and safety of apixaban vs. warfarin in venous thromboembolism patients with obesity and morbid obesity","volume":"10","author":"Cohen\n A","year":"2021","unstructured":"Cohen\n A\n , SahJ, LeeT, et al.\n Effectiveness and safety of apixaban vs. warfarin in venous thromboembolism patients with obesity and morbid obesity. J Clin Med. 2021;10(2):200. doi:10.3390\/jcm10020200"},{"issue":"6","key":"b16","series-title":"Adv Ther","first-page":"3003","article-title":"Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY","volume":"38","author":"Cohen\n AT","year":"2021","unstructured":"Cohen\n AT\n , PanS, ByonW, IlyasBS, TaylorT, LeeTC. Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. Adv Ther. 2021;38(6):3003-3018. doi:10.1007\/s12325-021-01716-8"},{"issue":"3","key":"b17","series-title":"Pharmacotherapy","first-page":"204","article-title":"Effectiveness and safety of direct oral anticoagulants versus warfarin in obese patients with acute venous thromboembolism","volume":"40","author":"Coons\n JC","year":"2020","unstructured":"Coons\n JC\n , AlbertL, BejjaniA, IasellaCJ. Effectiveness and safety of direct oral anticoagulants versus warfarin in obese patients with acute venous thromboembolism. Pharmacotherapy. 2020;40(3):204-210. doi:10.1002\/phar.2369"},{"key":"b18","series-title":"Thromb Res","first-page":"56","article-title":"Anticoagulant therapies and outcomes in obese patients with acute venous thromboembolism","volume":"187","author":"Quan\n S","year":"2020","unstructured":"Quan\n S\n , SmithJ, WuC, KoshmanSL, NguyenB, BungardTJ. Anticoagulant therapies and outcomes in obese patients with acute venous thromboembolism. Thromb Res. 2020;187:56-62. doi:10.1016\/j.thromres.2020.01.011"},{"key":"b19","series-title":"Blood","first-page":"3675","article-title":"Efficacy and safety of direct oral anticoagulants in obese patients with venous thromboembolism","volume":"134","author":"Sa\n RA","year":"2019","unstructured":"Sa\n RA\n , Al-AniF, Lazo-LangnerA, LouzadaML. Efficacy and safety of direct oral anticoagulants in obese patients with venous thromboembolism. Blood. 2019;134(suppl_1):3675. doi:10.1182\/blood-2019-121765"},{"issue":"4","key":"b20","series-title":"Ann Pharmacother","first-page":"344","article-title":"Rivaroxaban versus warfarin for stroke prevention and venous thromboembolism treatment in extreme obesity and high body weight","volume":"54","author":"Perales\n IJ","year":"2020","unstructured":"Perales\n IJ\n , San AgustinK, DeAngeloJ, CampbellAM. Rivaroxaban versus warfarin for stroke prevention and venous thromboembolism treatment in extreme obesity and high body weight. Ann Pharmacother. 2020;54(4):344-350. doi:10.1177\/1060028019886092"},{"issue":"2","key":"b21","series-title":"Pharmacotherapy","first-page":"112","article-title":"Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI \u226550 kg\/m2","volume":"42","author":"O'Kane\n CP","year":"2022","unstructured":"O'Kane\n CP\n , AvalonJCO, LacosteJL, et al.\n Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI \u226550 kg\/m2. Pharmacotherapy. 2022;42(2):112-118. doi:10.1002\/phar.2651"},{"issue":"9","key":"b22","series-title":"Pharmacotherapy","first-page":"907","article-title":"Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017","volume":"38","author":"Zhu\n J","year":"2018","unstructured":"Zhu\n J\n , AlexanderGC, NazarianS, SegalJB, WuAW. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017. Pharmacotherapy. 2018;38(9):907-920. doi:10.1002\/phar.2158"}],"container-title":["Texas Heart Institute Journal"],"original-title":[],"link":[{"URL":"https:\/\/thij.kglmeridian.com\/view\/journals\/thij\/51\/1\/article-e238260.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/thij\/article-pdf\/doi\/10.14503\/THIJ-23-8260\/3411048\/i1526-6702-51-1-e238260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thij.kglmeridian.com\/downloadpdf\/journals\/thij\/51\/1\/article-e238260.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thij.kglmeridian.com\/downloadpdf\/journals\/thij\/51\/1\/article-e238260.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T15:38:17Z","timestamp":1730993897000},"score":1,"resource":{"primary":{"URL":"https:\/\/thij.kglmeridian.com\/view\/journals\/thij\/51\/1\/article-e238260.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":22,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.14503\/thij-23-8260","relation":{},"ISSN":["1526-6702","0730-2347"],"issn-type":[{"type":"electronic","value":"1526-6702"},{"type":"print","value":"0730-2347"}],"subject":[],"published":{"date-parts":[[2024]]}}}